Health
Gene Therapy Access Challenges
FDA-approved gene therapies for sickle cell disease offer hope to patients but face significant access challenges due to high costs. Meanwhile, Wall Street veteran Larry McDonald suggests Nike as a potential turnaround trade amid broader market concerns.
Coverage timeline — 2 articles
CNBC
FDA-approved gene therapies for sickle cell disease offer a chance to help patients, but factors including cost and access have slowed their use.
2026-10-16 13:19 UTC
MarketWatch
Larry McDonald says the S&P 500’s record chasing is hiding lots of companies with sliding stocks. He has ideas on how to play that.
2026-10-16 14:28 UTC